CLINICAL TRIALS PROFILE FOR ALMOREXANT
✉ Email this page to a colleague
Clinical Trials for Almorexant
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00606593 ↗ | Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia | Completed | Midnight Pharma, LLC | Phase 2 | A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia. |
NCT00608985 ↗ | Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia | Completed | Midnight Pharma, LLC | Phase 3 | A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia. |
NCT00640848 ↗ | Almorexant in Primary Insomnia | Completed | Midnight Pharma, LLC | Phase 1 | The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters. |
NCT01243060 ↗ | Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance | Completed | U.S. Army Medical Research and Development Command | N/A | In recent years, there has been increased focus on cognitive side effects of sleep-inducing medications that may contribute to unusual behavior during unexpected awakenings during the night. Concerns regarding these side effects have led to a class Food and Drug Administration (FDA) warning for all sleep-inducing medications. Almorexant is an experimental sleep-inducing medication in a new class of medications that is being extensively developed by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in the brain that function with proteins called hypocretins. The goal of this study is to evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep aid) or placebo. |
NCT01243060 ↗ | Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance | Completed | U.S. Army Medical Research and Materiel Command | N/A | In recent years, there has been increased focus on cognitive side effects of sleep-inducing medications that may contribute to unusual behavior during unexpected awakenings during the night. Concerns regarding these side effects have led to a class Food and Drug Administration (FDA) warning for all sleep-inducing medications. Almorexant is an experimental sleep-inducing medication in a new class of medications that is being extensively developed by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in the brain that function with proteins called hypocretins. The goal of this study is to evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep aid) or placebo. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Almorexant
Condition Name
Clinical Trial Locations for Almorexant
Trials by Country
Clinical Trial Progress for Almorexant
Clinical Trial Phase
Clinical Trial Sponsors for Almorexant
Sponsor Name